Xylem reported first-quarter 2026 orders of $2.2 billion, up 3% from a year earlier, with organic orders flat. Revenue rose 3% to $2.1 billion, while organic revenue was unchanged.
Net income attributable to Xylem was $193 million, or $0.79 per share, up 14% from the prior year on a per-share basis. Adjusted net income was $272 million, or $1.12 per share, up 9%.
Net income margin increased 90 basis points to 9.1%. Adjusted EBITDA margin improved 20 basis points to 20.6%.
Xylem said productivity savings and price realization more than offset inflation, mix and lower volumes, helping drive the margin expansion.
For the full year, the company raised its reported revenue outlook to about $9.2 billion to $9.3 billion, from a prior range of 1% to 3% growth to a new range of 2% to 3% growth. Organic revenue growth guidance remained at 2% to 4%.
Adjusted EBITDA margin is now expected at 22.9% to 23.3%, up 70 to 110 basis points from 2025 adjusted results. Full-year adjusted earnings per share guidance remained at $5.35 to $5.60. Free cash flow margin was left unchanged at 10.2% to 11.0%. Following these announcements, the company's shares moved -0.19%, and are now trading at a price of $121.46. Check out the company's full 8-K submission here.
